Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure
Clinical trial NCT06334757 · UNKNOWN
Trial details
- NCT number
- NCT06334757
- Sponsor
- Henan Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-08
- Primary completion
- 2024-08-31
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.